Oxytocin (OT) and its receptor (OT-R) are implicated in the aetiology of autism spectrum disorders (ASDs) and OT-R is a potential target for therapeutic intervention. We report here the design and pharmacological activity of a second-generation OT-R agonist that is more potent and selective than OT itself both in vitro and in vivo, in two animal models of autism after peripheral and oral administration. The preclinical potential of this new lead compound, LIT-002, is also evaluated and discussed.